neostigmine has been researched along with Anesthesia in 125 studies
Neostigmine: A cholinesterase inhibitor used in the treatment of myasthenia gravis and to reverse the effects of muscle relaxants such as gallamine and tubocurarine. Neostigmine, unlike PHYSOSTIGMINE, does not cross the blood-brain barrier.
neostigmine : A quaternary ammonium ion comprising an anilinium ion core having three methyl substituents on the aniline nitrogen, and a 3-[(dimethylcarbamoyl)oxy] substituent at position 3. It is a parasympathomimetic which acts as a reversible acetylcholinesterase inhibitor.
Anesthesia: A state characterized by loss of feeling or sensation. This depression of nerve function is usually the result of pharmacologic action and is induced to allow performance of surgery or other painful procedures.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the onset of muscle relaxation using intravenous vecuronium and cisatracurium and assessed the ability of neostigmine to antagonize (reverse) this effect." | 9.08 | The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia. ( Fontenot, JP; Stevens, JB; Walker, SC, 1997) |
| "Ninety-nine ASA physical status 1 or 2 patients undergoing elective surgical procedures under nitrous oxide/opioid/barbiturate anesthesia were studied." | 7.69 | The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ( Abalos, A; Abou-Donia, MM; Belmont, MR; Eppich, L; Lien, CA; Quessy, S; Savarese, JJ, 1995) |
| "To examine the effects of discontinuing sevoflurane or isoflurane anesthesia (1 minimum alveolar anesthetic concentration [MAC] of end-tidal concentrations, together with 66% N2O/O2) on the reversal of vecuronium-induced neuromuscular blockade (an initial dose = 100 micrograms/kg), the electromyographic response of the abductor digiti minimi was monitored at 20-s intervals after train-of-four (TOF) stimulation of the ulnar nerve in 192 ASA grades I and II patients." | 7.69 | Inadequate antagonism of vecuronium-induced neuromuscular block by neostigmine during sevoflurane or isoflurane anesthesia. ( Fujita, T; Morita, T; Saito, S; Sato, H; Sugaya, T; Tsukagoshi, H, 1995) |
| " Sugammadex exhibits advantages over indirect reversal agent acetylcholinesterase inhibitor neostigmine with less adverse effects." | 5.72 | Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate. ( Chang, HC; Lee, MJ; Lee, SO; Liu, SY; Wong, CS, 2022) |
| "Pipecuronium bromide is a new steroidal non-depolarizing muscle relaxant currently under investigation." | 5.28 | A dose-response evaluation of pipecuronium bromide in elderly patients under balanced anesthesia. ( Azad, SS; Beach, CA; Goldberg, ME; Larijani, GE; Marr, AT; Seltzer, JL, 1989) |
| "Anesthesia was performed with thiopental sodium, fentanyl, halothane, nitrous oxide, and atracurium or vecuronium." | 5.08 | Time to peak effect of neostigmine at antagonism of atracurium- or vecuronium-induced neuromuscular block. ( Bülow, K; Helbo-Hansen, HS; Kirkegaard-Nielsen, H; Lindholm, P; Severinsen, IK, 1995) |
| "We investigated the onset of muscle relaxation using intravenous vecuronium and cisatracurium and assessed the ability of neostigmine to antagonize (reverse) this effect." | 5.08 | The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia. ( Fontenot, JP; Stevens, JB; Walker, SC, 1997) |
| "Alcuronium and pancuronium were compared as muscle relaxants in a randomized and double-blind trial in routine clinical circumstances during combined balanced anesthesia in 40 female patients." | 5.05 | A double-blind clinical trial comparing alcuronium with pancuronium. ( Ertama, P; Mattila, MA; Schivute, M, 1982) |
| "Ninety-nine ASA physical status 1 or 2 patients undergoing elective surgical procedures under nitrous oxide/opioid/barbiturate anesthesia were studied." | 3.69 | The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia. ( Abalos, A; Abou-Donia, MM; Belmont, MR; Eppich, L; Lien, CA; Quessy, S; Savarese, JJ, 1995) |
| "To examine the effects of discontinuing sevoflurane or isoflurane anesthesia (1 minimum alveolar anesthetic concentration [MAC] of end-tidal concentrations, together with 66% N2O/O2) on the reversal of vecuronium-induced neuromuscular blockade (an initial dose = 100 micrograms/kg), the electromyographic response of the abductor digiti minimi was monitored at 20-s intervals after train-of-four (TOF) stimulation of the ulnar nerve in 192 ASA grades I and II patients." | 3.69 | Inadequate antagonism of vecuronium-induced neuromuscular block by neostigmine during sevoflurane or isoflurane anesthesia. ( Fujita, T; Morita, T; Saito, S; Sato, H; Sugaya, T; Tsukagoshi, H, 1995) |
| "08 mg/kg), 36 surgical patients undergoing barbiturate/halothane anesthesia were given edrophonium 0." | 3.67 | [Antagonism of an intubation dose of vecuronium]. ( Baar, H; Lazarus, G; Sold, M, 1987) |
| "The effects of two anticholinesterases, galanthamine and neostigmine, on ACTH and, in some cases, cortisol were compared in 16 patients undergoing relaxant anaesthesia and surgery for varicose veins." | 3.66 | The effect of galanthamine hydrobromide on plasma ACTH in patients undergoing anaesthesia and surgery. ( Cozanitis, D; Dessypris, A; Nuuttila, K, 1980) |
| "This contracture is not prevented or relieved by regional anaesthesia or muscle relaxants." | 2.38 | [Anesthesia in myotonia]. ( Lienhart, A, 1989) |
| " Sugammadex exhibits advantages over indirect reversal agent acetylcholinesterase inhibitor neostigmine with less adverse effects." | 1.72 | Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate. ( Chang, HC; Lee, MJ; Lee, SO; Liu, SY; Wong, CS, 2022) |
| "Pretreatment with neostigmine completely prevented the clonidine-induced attenuation of the hypercapnic cerebral vasodilation attenuated by intrathecal clonidine (16% +/- 7%, 15% +/- 6%, 12% +/- 6%, and 16% +/- 8%, respectively)." | 1.33 | Intrathecal neostigmine prevents intrathecal clonidine from attenuating hypercapnic cerebral vasodilation in rabbits. ( Dohi, S; Iida, H; Iida, M; Kumazawa, M; Sumi, K; Takenaka, M; Tanahashi, S, 2005) |
| "Neostigmine produced an increase in TOF ratio in 52 patients and a decrease in 8." | 1.29 | Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium. ( Caldwell, JE, 1995) |
| "Suramin was without effect on heart rate or blood pressure in the doses used." | 1.29 | Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat. ( Agoston, S; Henning, RH; Houwertjes, M; Nelemans, A, 1993) |
| "Pipecuronium bromide is a new steroidal non-depolarizing muscle relaxant currently under investigation." | 1.28 | A dose-response evaluation of pipecuronium bromide in elderly patients under balanced anesthesia. ( Azad, SS; Beach, CA; Goldberg, ME; Larijani, GE; Marr, AT; Seltzer, JL, 1989) |
| "1 The tetanic and single twitch responses to the adductor pollicis muscle were used to study the neuromuscular effects of repeated dosage of decamethonium in nine anaesthetized patients." | 1.26 | Tachyphylaxis after repeated dosage of decamethonium in anaesthetized man. ( Al-Azawi, S; Hughes, R; Payne, JP, 1982) |
| "Neostigmine was more effective than eserine or dyflos." | 1.24 | Perfusion of cerebral ventricles: assay of pharmacologically active substances in the effluent from the cisterna and the aqueduct. ( BHATTACHARYA, BK; FELDBERG, W, 1958) |
| "Tetraethylammonium was much more powerful than triethylcholine in this respect." | 1.24 | Triethylcholine compared with other substances affecting neuromuscular transmission. ( BOWMAN, WC; HEMSWORTH, BA; RAND, MJ, 1962) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 90 (72.00) | 18.7374 |
| 1990's | 18 (14.40) | 18.2507 |
| 2000's | 4 (3.20) | 29.6817 |
| 2010's | 10 (8.00) | 24.3611 |
| 2020's | 3 (2.40) | 2.80 |
| Authors | Studies |
|---|---|
| Chang, HC | 1 |
| Liu, SY | 1 |
| Lee, MJ | 1 |
| Lee, SO | 1 |
| Wong, CS | 1 |
| Chen, X | 1 |
| Bartels, K | 1 |
| Fernandez-Bustamante, A | 1 |
| Vidal Melo, MF | 1 |
| Brull, SJ | 1 |
| Naguib, M | 1 |
| Carron, M | 1 |
| Bertoncello, F | 1 |
| Ieppariello, G | 1 |
| Adami, C | 1 |
| Sanchez, RF | 1 |
| Monticelli, P | 1 |
| Øberg, E | 1 |
| Claudius, C | 1 |
| Wiese, AJ | 1 |
| Brosnan, RJ | 1 |
| Barter, LS | 1 |
| Fuchs-Buder, T | 1 |
| Meistelman, C | 1 |
| Alla, F | 1 |
| Grandjean, A | 1 |
| Wuthrich, Y | 1 |
| Donati, F | 1 |
| Weingarten, TN | 1 |
| Hofer, RE | 1 |
| Milone, M | 1 |
| Sprung, J | 2 |
| SLAUGHTER, D | 1 |
| Dahaba, AA | 1 |
| Bornemann, H | 1 |
| Hopfgartner, E | 1 |
| Ohran, M | 1 |
| Kocher, K | 1 |
| Liebmann, M | 1 |
| Wilfinger, G | 1 |
| Metzler, H | 1 |
| Watts, RW | 1 |
| London, JA | 1 |
| van Wijk, RM | 1 |
| Lui, YL | 1 |
| Geldner, G | 1 |
| Niskanen, M | 1 |
| Laurila, P | 1 |
| Mizikov, V | 1 |
| Hübler, M | 1 |
| Beck, G | 1 |
| Rietbergen, H | 1 |
| Nicolayenko, E | 1 |
| Heier, T | 1 |
| Clough, D | 1 |
| Wright, PM | 1 |
| Sharma, ML | 1 |
| Sessler, DI | 1 |
| Caldwell, JE | 2 |
| KOHLER, H | 1 |
| KOOTZ, F | 1 |
| VON EKESPARRE, W | 1 |
| JACOBSON, E | 1 |
| ADELMAN, MH | 1 |
| BRAUNIGER, JG | 1 |
| NICHTERN, S | 1 |
| SAXENA, PN | 1 |
| GUPTA, GP | 1 |
| BHATTACHARYA, BK | 1 |
| FELDBERG, W | 1 |
| CORRADO, AP | 1 |
| RAMOS, AO | 1 |
| DE ESCOBAR, CT | 1 |
| BOWMAN, WC | 1 |
| HEMSWORTH, BA | 1 |
| RAND, MJ | 1 |
| MCDONALD, I | 1 |
| MARITANO, M | 1 |
| QUERCI, M | 1 |
| YAMASHITA, K | 1 |
| MORI, S | 1 |
| ABE, M | 1 |
| OTA, M | 1 |
| NISHIGUCHI, M | 1 |
| MIYAZATO, Y | 1 |
| WALCOK, F | 1 |
| DOSTAL, J | 1 |
| RAWSTRON, RE | 1 |
| HUTCHINSON, BR | 2 |
| BERGMANN, H | 1 |
| POCTA, J | 1 |
| UHLIROVA, A | 1 |
| JENKINS, LC | 1 |
| CHANG, J | 1 |
| GRAVES, HB | 1 |
| RYAN, AR | 1 |
| BONO, F | 1 |
| LANZETTA, A | 1 |
| MAGGI, U | 1 |
| MAPELLI, A | 1 |
| BUSH, GH | 1 |
| BARAKA, A | 2 |
| HUNTER, AR | 2 |
| GREEN, VA | 1 |
| PRADHAN, SN | 1 |
| PANDEY, K | 1 |
| BADOLA, RP | 1 |
| LUKOMSKII, GI | 1 |
| MIKHELSON, VA | 1 |
| MANEVICH, AZ | 1 |
| SURIN, IuV | 1 |
| STOJANOV, EA | 1 |
| HEINONEN, VJ | 1 |
| PAASONEN, K | 1 |
| KEMP, SW | 1 |
| MORTON, HJ | 1 |
| KREUL, W | 1 |
| ORTH, OS | 1 |
| CAMPAN, L | 1 |
| Takenaka, M | 1 |
| Iida, H | 1 |
| Iida, M | 1 |
| Sumi, K | 1 |
| Kumazawa, M | 1 |
| Tanahashi, S | 1 |
| Dohi, S | 1 |
| Kopman, AF | 1 |
| Ball, C | 1 |
| Westhorpe, RN | 1 |
| Wirtavuori, K | 2 |
| Salmenperä, M | 2 |
| Tammisto, T | 3 |
| Krieg, N | 1 |
| Mazur, L | 1 |
| Booij, LH | 1 |
| Crul, JF | 1 |
| Wright, M | 1 |
| Aitkenhead, AR | 1 |
| Miller, RD | 2 |
| Rupp, SM | 2 |
| Fisher, DM | 1 |
| Cronnelly, R | 2 |
| Fahey, MR | 1 |
| Sohn, YJ | 1 |
| Cozanitis, D | 1 |
| Dessypris, A | 1 |
| Nuuttila, K | 2 |
| Cherepanova, VP | 1 |
| Danilov, AF | 1 |
| Khromov-Borisov, NV | 1 |
| Malygin, VV | 1 |
| Starshinova, LA | 1 |
| Torf, SF | 1 |
| Meakin, G | 1 |
| Sweet, PT | 1 |
| Bevan, JC | 1 |
| Bevan, DR | 1 |
| Punt-van Manen, JA | 1 |
| Müller, H | 1 |
| Kalenda, Z | 1 |
| Samra, SK | 1 |
| Pandit, U | 1 |
| Pandit, SK | 1 |
| Kothary, SP | 1 |
| Hughes, R | 3 |
| Brock-Utne, JG | 1 |
| Adams, B | 1 |
| Downing, JW | 1 |
| Gawley, TH | 1 |
| Dundee, JW | 1 |
| Klein, C | 1 |
| Hopkins, J | 2 |
| Beck, E | 2 |
| Burton, B | 2 |
| Klein, L | 1 |
| Schivute, M | 1 |
| Ertama, P | 2 |
| Mattila, MA | 1 |
| Al-Azawi, S | 1 |
| Payne, JP | 3 |
| Allwright, GT | 1 |
| Frankel, DZ | 1 |
| McCoy, EP | 1 |
| Mirakhur, RK | 1 |
| Belmont, MR | 1 |
| Lien, CA | 1 |
| Quessy, S | 1 |
| Abou-Donia, MM | 1 |
| Abalos, A | 1 |
| Eppich, L | 1 |
| Savarese, JJ | 2 |
| Morita, T | 1 |
| Tsukagoshi, H | 1 |
| Sugaya, T | 1 |
| Saito, S | 1 |
| Sato, H | 1 |
| Fujita, T | 1 |
| Stinson, LW | 1 |
| Lanier, WL | 1 |
| Lennon, RL | 1 |
| Milne, MR | 1 |
| Crosse, MM | 1 |
| Nielsen, HK | 1 |
| May, O | 1 |
| Iwasaki, H | 1 |
| Igarashi, M | 1 |
| Omori, H | 1 |
| Omote, K | 1 |
| Namiki, A | 1 |
| Backman, SB | 1 |
| Ralley, FE | 1 |
| Fox, GS | 1 |
| Henning, RH | 1 |
| Nelemans, A | 1 |
| Houwertjes, M | 1 |
| Agoston, S | 2 |
| Farber, SA | 1 |
| Kischka, U | 1 |
| Marshall, DL | 1 |
| Wurtman, RJ | 1 |
| Davis, L | 1 |
| Jayarajah, MJ | 1 |
| Toner, CC | 1 |
| Flynn, PJ | 1 |
| Motsch, J | 1 |
| Leuwer, M | 1 |
| Böttiger, BW | 1 |
| Bach, A | 1 |
| Schönstedt, R | 1 |
| Martin, E | 1 |
| Kirkegaard-Nielsen, H | 1 |
| Helbo-Hansen, HS | 1 |
| Lindholm, P | 1 |
| Severinsen, IK | 1 |
| Bülow, K | 1 |
| Meretoja, OA | 1 |
| Taivainen, T | 1 |
| Stevens, JB | 1 |
| Walker, SC | 1 |
| Fontenot, JP | 1 |
| Castellani, WJ | 1 |
| Srinivasan, V | 1 |
| Udayashankar, S | 1 |
| Lawrence, D | 1 |
| Livingston, A | 1 |
| Nampo, T | 1 |
| Kawashima, Y | 1 |
| Meguro, K | 1 |
| Aruga, K | 1 |
| Yoshikawa, H | 1 |
| Ohtani, Y | 1 |
| Tanimura, O | 1 |
| Takei, H | 1 |
| Geevarghese, KP | 1 |
| Shields, CB | 1 |
| Gray, LA | 1 |
| Grigg, KN | 1 |
| Mees, DE | 1 |
| Frederickson, EL | 1 |
| Thoren-Tolling, K | 1 |
| Lienhart, A | 1 |
| Azad, SS | 1 |
| Larijani, GE | 1 |
| Goldberg, ME | 1 |
| Beach, CA | 1 |
| Marr, AT | 1 |
| Seltzer, JL | 1 |
| McChristian, JW | 1 |
| Taboada, JA | 1 |
| Dernovoi, B | 1 |
| Barvais, L | 1 |
| Baurain, M | 1 |
| Lefebvre, R | 1 |
| d'Hollander, A | 1 |
| Sold, M | 1 |
| Lazarus, G | 1 |
| Baar, H | 1 |
| Reddy, FS | 1 |
| Dykes, MH | 1 |
| Cheng, SC | 1 |
| Cohen, H | 1 |
| Valle, RF | 1 |
| Hall, LW | 1 |
| Kellagher, RE | 1 |
| Watkins, SB | 1 |
| Jones, RM | 1 |
| Cashman, JN | 1 |
| Casson, WR | 1 |
| Broadbent, MP | 1 |
| De Jong, RH | 1 |
| Feldman, SA | 1 |
| Tyrrell, MF | 1 |
| Manani, G | 3 |
| Gritti, G | 3 |
| Vecchini, L | 1 |
| Manzin, E | 2 |
| Merli, GA | 1 |
| Monks, PS | 1 |
| Dechêne, JP | 1 |
| Desrosiers, R | 1 |
| Bédard, O | 1 |
| Lumb, WV | 1 |
| Telivuo, L | 1 |
| Aalto-Setälä, M | 1 |
| Appelqvist, R | 1 |
| Kaljunen, A | 1 |
| Karhunen, U | 1 |
| Welling, I | 1 |
| Brown, TC | 1 |
| Vetten, KB | 1 |
| Ramamurthy, S | 1 |
| Shaker, MH | 1 |
| Winnie, AP | 1 |
| Dalal, FY | 1 |
| Bennett, EJ | 1 |
| Raj, PP | 1 |
| Lee, DG | 1 |
| Roberts, FW | 1 |
| Ylitalo, P | 1 |
| Bálint, G | 1 |
| Tominaga, T | 1 |
| Iwai, S | 1 |
| Mitsukawa, H | 1 |
| Horita, K | 1 |
| Suzuki, G | 1 |
| Gravenstein, JS | 1 |
| Galzigna, L | 1 |
| Grieco, R | 1 |
| Benad, G | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multi-center, Randomized, Parallel-group, Comparative, Active-controlled, Safety-assessor Blinded Trial in Adult Subjects Comparing the Efficacy and Safety of Sugammadex (SCH 900616, ORG 25969) Administered at 1-2 PTC With Neostigmine Administered at Re[NCT00724932] | Phase 3 | 140 participants (Actual) | Interventional | 2008-07-16 | Completed | ||
| The Effects of Deep Neuromuscular Blockade During Robot-assisted Transaxillary Thyroidectomy on Postoperative Pain and Sensory Change; Prospective Randomized Control Trial[NCT03871387] | 88 participants (Actual) | Interventional | 2019-03-04 | Completed | |||
| Comparing Deep Neuromuscular Block and Moderate Neuromuscular Block in Patients Undergoing Laparoscopic Gynaecological Surgeries: Impact on Surgical Satisfaction of Operating Conditions and Patient Satisfaction[NCT02794714] | Phase 4 | 0 participants (Actual) | Interventional | 2016-06-30 | Withdrawn (stopped due to unresolved budget issues) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The monitoring of clinical signs of recovery was to be conducted based on the routine anesthetic procedures at each site. (NCT00724932)
Timeframe: Up to PACU discharge (up to ~4.5 hours)
| Intervention | participants (Number) |
|---|---|
| Sugammadex | NA |
| Neostigmine | NA |
Thirty days after administration of IMP, female participants of childbearing potential were asked whether they became pregnant during the trial and male participants were asked whether their partner (if of childbearing potential) became pregnant during the trial. (NCT00724932)
Timeframe: Up to 30 days after IMP administration
| Intervention | participants (Number) |
|---|---|
| Sugammadex | 0 |
| Neostigmine | 0 |
Clinical evidence of reoccurrence of NMB or residual NMB was assessed by oxygen saturation (by pulse oximetry) and breath frequency measurements as per routine practice after anesthesia and neuromuscular monitoring. (NCT00724932)
Timeframe: Up to 24 hours after IMP administration
| Intervention | participants (Number) |
|---|---|
| Sugammadex | 1 |
| Neostigmine | 0 |
Any evidence of events due to a possible interaction of sugammadex with endogenous compounds or with exogenous compounds other than rocuronium, was to be recorded. (NCT00724932)
Timeframe: Up to 7 days after IMP administration
| Intervention | participants (Number) |
|---|---|
| Sugammadex Only | 0 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the 1st and 4th twitches, respectively, after TOF stimulation. The T4/T1 Ratio is expressed as a decimal of up to 1.0. A higher ratio indicates greater recovery from NMB. A decline in the T4/T1 ratio from >=0.9 (indicating a recovery from NMB) to <0.8 for at least three consecutive TOF values was considered to be a reoccurrence of NMB. (NCT00724932)
Timeframe: Up to 30 minutes after IMP administration
| Intervention | participants (Number) |
|---|---|
| Sugammadex | 0 |
| Neostigmine | 0 |
Events were to be collected for the entire period of neuromuscular transmission monitoring and were defined as an occurrence that resulted or could have resulted in: death; a serious deterioration in the state of health of a user; an occurrence which might, if it recurred, lead to death or serious deterioration in health; inaccuracy as well as any inadequacy in the labeling or instructions which could cause misuse or incorrect maintenance or adjustment which might lead to a death or serious deterioration in health; an examination of the medical device or the information supplied with the medical device indicated some factor with the potential for an incident involving death or serious deterioration in health; malfunction or deterioration in characteristics and/or performance of a medical device, which might lead to death, or serious deterioration in health; technical/medical recalls involving risk of death or serious deterioration in the state of health of the user. (NCT00724932)
Timeframe: From induction of anesthesia to recovery from NMB (up to ~3 hours)
| Intervention | participants (Number) |
|---|---|
| Sugammadex | 0 |
| Neostigmine | 0 |
The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From actual Operating Room discharge to actual PACU discharge (up to ~4.4 hours)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 264 |
| Neostigmine | 207 |
The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From actual Operating Room discharge to PACU discharge ready (up to ~30 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 24 |
| Neostigmine | 29 |
The time of Operating Room admission was defined as the time at which the participant was physically placed into the Operating Room. The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From Operating Room admission to actual Operating Room discharge (up to ~3 hours)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 158 |
| Neostigmine | 169 |
The time of Operating Room admission was defined as the time at which the participant was physically placed into the Operating Room. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of ≥0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From Operating Room admission to Operating Room discharge ready (up to ~3 hours)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 154 |
| Neostigmine | 165 |
The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of Operating Room discharge was defined as the actual time the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From Operating Room discharge ready to actual Operating Room discharge (up to ~5 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 4 |
| Neostigmine | 5 |
The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From Operating Room discharge ready to actual PACU discharge (up to ~4.5 hours)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 268 |
| Neostigmine | 210 |
The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From Operating Room discharge ready to PACU discharge ready (up to ~33 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 28 |
| Neostigmine | 33 |
The time of PACU admit was defined as the actual time the participant was admitted to the PACU. The time of PACU discharge was defined as the actual time the participant was discharged from the PACU. (NCT00724932)
Timeframe: From PACU admit to actual PACU discharge (up to ~4.3 hours)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 260 |
| Neostigmine | 203 |
The time of PACU admit was defined as the actual time the participant was admitted to the PACU. The time of PACU discharge ready was defined as the time at which the participant had a Modified Aldrete Score >=9. The Modified Aldrete Score was to be assessed at PACU arrival, at 5, 15, 30, 45, 60 minutes after PACU arrival and every 15 minutes thereafter (if applicable) until the participant was ready to be discharged from the PACU. The Modified Aldrete Postoperative Recovery Score (range = 0-10) is calculated based on scores of 0 to 2 each for Activity, Respiration, Circulation, Consciousness and Oxygen Saturation, with a higher score indicating increased postoperative recovery. (NCT00724932)
Timeframe: From PACU admit to PACU discharge ready (up to ~25 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 20 |
| Neostigmine | 25 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.7 (ranging from ~2 minutes to ~5 minutes)
| Intervention | minutes (Geometric Mean) |
|---|---|
| Sugammadex | 1.6 |
| Neostigmine | 4.1 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.8 (ranging from ~2 minutes to ~6 minutes)
| Intervention | minutes (Geometric Mean) |
|---|---|
| Sugammadex | 1.9 |
| Neostigmine | 5.6 |
Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached >= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 ratio to 0.9 (ranging from ~2 minutes to ~9 minutes)
| Intervention | minutes (Geometric Mean) |
|---|---|
| Sugammadex | 2.4 |
| Neostigmine | 8.4 |
The time of 1-2 PTC refers to when 1-2 twitches are generated after tetanic stimulation. Time to 1-2 PTC is the time point of the last single twitch >0 or baseline (in case of noise or direct stimulation) within the sequence of a PTC measurement. 1-2 PTC was the target depth of NMB at which sugammadex was to be administered. (NCT00724932)
Timeframe: From last dose of rocuronium to 1-2 PTC (up to ~9 minutes)
| Intervention | minutes (Geometric Mean) |
|---|---|
| Sugammadex Only | 8.9 |
The time of reappearance of T2 refers to when the second twitch reappears after TOF stimulation. Reappearance of T2 was the target depth of NMB at which neostigmine was to be administered. (NCT00724932)
Timeframe: From last dose of rocuronium to reappearance of T2 (up to ~26 minutes)
| Intervention | minutes (Geometric Mean) |
|---|---|
| Neostigmine Only | 25.6 |
The time of IMP administration was defined as the actual time at which IMP administration was started. The time of Operating Room discharge was defined as the actual time at which the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From start of IMP administration to actual Operating Room discharge (up to ~26 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 19 |
| Neostigmine | 26 |
The time of IMP administration was defined as the actual time at which IMP administration was started. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From start of IMP administration to Operating Room discharge ready (up to ~21 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 15 |
| Neostigmine | 21 |
The time of IMP administration was defined as the actual time at which IMP administration was started. The time of tracheal extubation was defined as the actual time at which the participant was extubated. (NCT00724932)
Timeframe: From start of IMP administration to tracheal extubation (up to ~21 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 14 |
| Neostigmine | 21 |
The time of tracheal extubation was defined as the actual time at which the participant was extubated. The time of Operating Room discharge was defined as the actual time at which the participant was discharged from the Operating Room. (NCT00724932)
Timeframe: From tracheal extubation to actual OR discharge (up to ~5 minutes)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 5 |
| Neostigmine | 5 |
The time of tracheal extubation was defined as the actual time at which the participant was extubated. The time of Operating Room discharge ready was defined as time at which the participant had T4/T1 ratio of >=0.9 and the participant's wound dressing was in place. (NCT00724932)
Timeframe: From tracheal extubation to Operating Room discharge ready (up to ~1 minute)
| Intervention | minutes (Mean) |
|---|---|
| Sugammadex | 1 |
| Neostigmine | 0 |
Diastolic Blood Pressure was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)
| Intervention | mm Hg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Screening | Pre-rocuronium | Pre-IMP | 2 minutes post-IMP (N=65, N=65) | 5 minutes post-IMP | 10 minutes post-IMP (N=66, N=66) | 30 minutes post-IMP (N=65, N=66) | Post-anesthetic visit (N=66, N=66) | |
| Neostigmine | 82.8 | 58.3 | 72.5 | 72.6 | 69.2 | 68.7 | 73.1 | 75.2 |
| Sugammadex | 80.9 | 58.2 | 72.8 | 73.4 | 72.4 | 71.8 | 74.3 | 76.7 |
Heart Rate was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)
| Intervention | beats per minute (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Screening | Pre-rocuronium | Pre-IMP | 2 minutes post-IMP (N=65, N=65) | 5 minutes post-IMP | 10 minutes post-IMP (N=66, N=66) | 30 minutes post-IMP (N=65, N=66) | Post-anesthetic visit (N=66, N=66) | |
| Neostigmine | 74.6 | 63.6 | 68.0 | 65.3 | 57.1 | 56.3 | 65.1 | 71.9 |
| Sugammadex | 72.9 | 63.4 | 68.3 | 66.0 | 64.9 | 67.3 | 73.1 | 72.7 |
Systolic Blood Pressure was measured at screening, before start of rocuronium administration, before start of IMP administration, at 2, 5, 10, 30 minutes post-IMP administration, and at the post-anesthetic visit (the day after surgery). (NCT00724932)
Timeframe: At screening, pre-rocuronium, pre-IMP, at 2, 5, 10, and 30 minutes post-IMP, and at the post-anesthetic visit (the day after surgery)
| Intervention | mm Hg (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Screening | Pre-rocuronium | Pre-IMP | 2 minutes post-IMP (N=65, N=65) | 5 minutes post-IMP | 10 minutes post-IMP (N=66, N=66) | 30 minutes post-IMP (N=65, N=66) | Post-anesthetic visit (N=66, N=66) | |
| Neostigmine | 133.9 | 101.6 | 121.3 | 122.5 | 118.0 | 119.3 | 131.7 | 125.4 |
| Sugammadex | 132.7 | 98.2 | 122.1 | 122.5 | 122.6 | 124.0 | 132.9 | 127.3 |
An AE is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body, whether or not considered related to the use of the product. Participants were monitored for occurrence AEs for up to 7 days after last dose IMP. Pre-treatment refers to the period from signing of the informed consent up to start of IMP administration. Post-treatment refers to the period from start of IMP administration to 7 days after IMP administration. (NCT00724932)
Timeframe: From signing of informed consent to end of trial (7 days after surgery)
| Intervention | participants (Number) | |
|---|---|---|
| Pre-treatment non-serious AE | Post-treatment non-serious AE | |
| Neostigmine | 34 | 65 |
| Sugammadex | 38 | 65 |
"An SAE is defined as any untoward medical occurrence that at any dose: results in death; is life-threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; or is a congenital anomaly/birth defect.~Participants were monitored for occurrence SAEs for up to 7 days after last dose IMP. Pre-treatment refers to the period from signing of the informed consent up to start of IMP administration. Post-treatment refers to the period from start of IMP administration to 7 days after IMP administration." (NCT00724932)
Timeframe: From signing of informed consent to end of trial (7 days after surgery)
| Intervention | participants (Number) | |
|---|---|---|
| Pre-treatment SAE | Post-treatment SAE | |
| Neostigmine | 0 | 6 |
| Sugammadex | 1 | 4 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). Faster times to recovery of the T4/T1 Ratios to 0.5 and 0.6 indicate faster recoveries from NMB. (NCT00724932)
Timeframe: From start of IMP administration to recovery of T4/T1 Ratio to 0.5 and 0.6 (ranging from ~1 minute to ~4 minutes)
| Intervention | minutes (Geometric Mean) | |
|---|---|---|
| Recovery of T4/T1 Ratio to 0.5 | Recovery of T4/T1 Ratio to 0.6 | |
| Neostigmine | 2.8 | 3.4 |
| Sugammadex | 1.3 | 1.5 |
Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds & assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the magnitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0). A faster time to recovery of the T4/T1 Ratio indicates a faster recovery from NMB. (NCT00724932)
Timeframe: From start of last dose of rocuronium to recovery of T4/T1 Ratio to 0.5, 0.6, 0.7, 0.8 and 0.9 (ranging from ~12 minutes to ~36 minutes)
| Intervention | minutes (Geometric Mean) | ||||
|---|---|---|---|---|---|
| Recovery of T4/T1 ratio to 0.5 | Recovery of T4/T1 ratio to 0.6 | Recovery of T4/T1 ratio to 0.7 | Recovery of T4/T1 ratio to 0.8 | Recovery of T4/T1 ratio to 0.9 (N=65, N=61) | |
| Neostigmine | 30.0 | 30.7 | 31.6 | 33.2 | 35.2 |
| Sugammadex | 11.7 | 11.9 | 12.1 | 12.5 | 13.3 |
8 reviews available for neostigmine and Anesthesia
| Article | Year |
|---|---|
Profile of sugammadex for reversal of neuromuscular blockade in the elderly: current perspectives.
Topics: Aged; Androstanols; Anesthesia; Cholinesterase Inhibitors; gamma-Cyclodextrins; Humans; Middle Aged; | 2018 |
[Possible clinical potential in reverting muscular block with sugammadex in anaesthesia and surgery].
Topics: Androstanols; Anesthesia; Anesthesia Recovery Period; gamma-Cyclodextrins; Humans; Intubation, Intra | 2013 |
Pharmacologic effects of ketamine and its use in veterinary medicine.
Topics: Amphetamine; Anesthesia; Animals; Antipsychotic Agents; Brain; Cardiovascular System; Cats; Cattle; | 1982 |
Anaesthesia and bowel surgery.
Topics: Analgesics, Opioid; Anesthesia; Anesthesia, Conduction; Anesthetics; Animals; Carbon Dioxide; Gastro | 1984 |
Clinical pharmacology of vecuronium and atracurium.
Topics: Acid-Base Equilibrium; Adolescent; Adult; Age Factors; Aged; Anesthesia; Anesthesia, Obstetrical; At | 1984 |
[Anesthesia in myotonia].
Topics: Anesthesia; Contracture; Disease Susceptibility; Female; Humans; Hypercapnia; Male; Malignant Hypert | 1989 |
Clinical relaxation: current controversy.
Topics: Androstane-3,17-diol; Anesthesia; Atracurium; Cholinesterase Inhibitors; Humans; Intubation, Intratr | 1986 |
Muscle relaxants in small animal anesthesia.
Topics: Anesthesia; Animals; Cats; Cholinesterases; Decamethonium Compounds; Dogs; Edrophonium; Gallamine Tr | 1972 |
17 trials available for neostigmine and Anesthesia
| Article | Year |
|---|---|
Effects of acetylcholinesterase inhibition on quality of recovery from isoflurane-induced anesthesia in horses.
Topics: Anesthesia; Anesthesia Recovery Period; Anesthetics, Inhalation; Animals; Cholinesterase Inhibitors; | 2014 |
Effect of sugammadex or neostigmine neuromuscular block reversal on bispectral index monitoring of propofol/remifentanil anaesthesia.
Topics: Adolescent; Adult; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; C | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
A randomised controlled trial comparing sugammadex and neostigmine at different depths of neuromuscular blockade in patients undergoing laparoscopic surgery.
Topics: Adult; Aged; Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Intravenous; Choline | 2012 |
Attempts to reduce respiratory complications following upper abdominal operations.
Topics: Abdomen; Adolescent; Adult; Anesthesia; Carbon Dioxide; Hot Temperature; Humans; Humidity; Middle Ag | 1981 |
A double-blind clinical trial comparing alcuronium with pancuronium.
Topics: Adult; Alcuronium; Anesthesia; Clinical Trials as Topic; Double-Blind Method; Female; Hemodynamics; | 1982 |
Comparison of the effects of neostigmine and edrophonium on the duration of action of suxamethonium.
Topics: Adult; Anesthesia; Atracurium; Cholinesterase Inhibitors; Cholinesterases; Edrophonium; Female; Huma | 1995 |
Train-of-four recovery after pharmacologic antagonism of pancuronium-, pipecuronium-, and doxacurium-induced neuromuscular block in anaesthetized humans.
Topics: Anesthesia; Female; Humans; Isoquinolines; Male; Neostigmine; Neuromuscular Junction; Neuromuscular | 1995 |
[The optimal administration time for neostigmine following atracurium blockade. Kinetics of antagonists].
Topics: Adult; Aging; Anesthesia; Atracurium; Body Weight; Electric Stimulation; Female; Humans; Neostigmine | 1994 |
Evaluation of neuromuscular effects and antagonism of rocuronium bromide: a preliminary report.
Topics: Adolescent; Adult; Androstanols; Anesthesia; Cholinesterase Inhibitors; Double-Blind Method; Edropho | 1995 |
Dose-response, time-course of action and recovery of rocuronium bromide in children during halothane anaesthesia.
Topics: Androstanols; Anesthesia; Anesthesia Recovery Period; Anesthetics, Inhalation; Blood Pressure; Child | 1995 |
Time to peak effect of neostigmine at antagonism of atracurium- or vecuronium-induced neuromuscular block.
Topics: Adult; Anesthesia; Atracurium; Cholinesterase Inhibitors; Dose-Response Relationship, Drug; Electric | 1995 |
Cisatracurium during halothane and balanced anaesthesia in children.
Topics: Anesthesia; Anesthesia, Inhalation; Anesthetics, Combined; Anesthetics, Inhalation; Atracurium; Bloo | 1996 |
The clinical neuromuscular pharmacology of cisatracurium versus vecuronium during outpatient anesthesia.
Topics: Adolescent; Adult; Ambulatory Surgical Procedures; Anesthesia; Atracurium; Dose-Response Relationshi | 1997 |
Controlled relaxation. II. Clinical management of muscle-relaxant administration.
Topics: Abdominal Muscles; Adult; Aged; Anesthesia; Clinical Trials as Topic; Electric Stimulation; Female; | 1966 |
A new steroid muscle relaxant. Dacuronium-NB.68 (Organon).
Topics: Androstanes; Anesthesia; Atropine; Clinical Trials as Topic; Gallamine Triethiodide; Halothane; Huma | 1970 |
The reversal of non-depolarising relaxants. A comparison of tubocurarine, gallamine and pancuronium.
Topics: Androstanes; Anesthesia; Atropine; Electric Stimulation; Gallamine Triethiodide; Humans; Neostigmine | 1972 |
A clinical study of pancuronium, a new muscular relaxant for abdominal surgery.
Topics: Abdomen; Adolescent; Adult; Age Factors; Aged; Androstanes; Anesthesia; Atropine; Body Weight; Clini | 1972 |
100 other studies available for neostigmine and Anesthesia
| Article | Year |
|---|---|
Sugammadex reversal of muscle relaxant blockade provided less Post-Anesthesia Care Unit adverse effects than neostigmine/glycopyrrolate.
Topics: Anesthesia; Glycopyrrolate; Humans; Iatrogenic Disease; Muscles; Neostigmine; Neuromuscular Blockade | 2022 |
Comment on "Sugammadex reversal of muscle relaxant blockade provided less post-anesthesia care unit adverse effects than neostigmine/glycopyrrolate".
Topics: Anesthesia; Drug-Related Side Effects and Adverse Reactions; Glycopyrrolate; Humans; Muscles; Neosti | 2023 |
Reversal of neuromuscular block: what are the costs?
Topics: Anesthesia; Cholinesterase Inhibitors; Costs and Cost Analysis; Humans; Neostigmine; Neuromuscular B | 2023 |
How to Catch Unicorns (and Other Fairytales).
Topics: Anesthesia; Cholinesterase Inhibitors; Humans; Neostigmine; Neuromuscular Blockade | 2018 |
Use of atracurium and its reversal with neostigmine in 14 pet rabbits undergoing ophthalmic surgery: a retrospective study.
Topics: Anesthesia; Animals; Atracurium; Cholinesterase Inhibitors; Neostigmine; Neuromuscular Nondepolarizi | 2019 |
Antagonism of low degrees of atracurium-induced neuromuscular blockade: dose-effect relationship for neostigmine.
Topics: Anesthesia; Anesthesia Recovery Period; Atracurium; Cholinesterase Inhibitors; Dose-Response Relatio | 2010 |
Anesthesia and myotonic dystrophy type 2: a case series.
Topics: Adult; Anesthesia; Anesthetics, Inhalation; Cholinesterase Inhibitors; Female; Humans; Intraoperativ | 2010 |
The modifying action of neostigmine on pain threshold responses to various opiates.
Topics: Analgesics, Opioid; Anesthesia; Humans; Neostigmine; Pain Threshold | 1946 |
The influence of unrestricted use of sugammadex on clinical anaesthetic practice in a tertiary teaching hospital.
Topics: Adult; Aged; Aged, 80 and over; Androstanols; Anesthesia; Cholinesterase Inhibitors; Drug Utilizatio | 2012 |
The influence of mild hypothermia on the pharmacokinetics and time course of action of neostigmine in anesthetized volunteers.
Topics: Adult; Anesthesia; Female; Humans; Hypothermia, Induced; Male; Neostigmine; Neuromuscular Nondepolar | 2002 |
[Short note on clinical tests of neoeserin as a curare antidote].
Topics: Anesthesia; Antidotes; Curare; Intubation, Intratracheal; Neostigmine; Trachea | 1953 |
[The potentiating effects of prostigmine in narconumal narcoses and postoperative analgesic medication].
Topics: Analgesia; Analgesics; Anesthesia; Anesthesia and Analgesia; Barbiturates; Neostigmine | 1953 |
The electrocardiographic effects of intravenous administration of neostigmine and atropine during cyclopropane anesthesia.
Topics: Administration, Intravenous; Analgesia; Anesthesia; Anesthesia and Analgesia; Atropine; Cyclopropane | 1954 |
[Practical applications of prostigmine in anesthesia].
Topics: Anesthesia; Anesthesiology; Neostigmine | 1954 |
Neurological agents in child psychiatry.
Topics: Analgesia; Anesthesia; Anesthesia and Analgesia; Caffeine; Child; Child Psychiatry; Humans; Morphine | 1957 |
Potentiating effect of prostigmine on morphine-induced analgesia.
Topics: Analgesia; Anesthesia; Anesthesia and Analgesia; Humans; Morphine; Neostigmine; Pain Management | 1957 |
Perfusion of cerebral ventricles: assay of pharmacologically active substances in the effluent from the cisterna and the aqueduct.
Topics: Acetylcholine; Anesthesia; Animals; Biological Assay; Blood-Brain Barrier; Cats; Cerebral Aqueduct; | 1958 |
Neuro-muscular blockade by neomycin, potentiation by ether anesthesia and d-tubucurarine and antagonism by calcium and prostigmine.
Topics: Anesthesia; Calcium; Calcium, Dietary; Curare; Ether; Ethers; Neomycin; Neostigmine; Neuromuscular J | 1959 |
Triethylcholine compared with other substances affecting neuromuscular transmission.
Topics: Acetylcholine; Action Potentials; Anesthesia; Animals; Bis-Trimethylammonium Compounds; Cats; Cholin | 1962 |
A CASE OF SUXAMETHONIUM SENSITIVITY.
Topics: Anesthesia; Anesthesiology; Apnea; Atropine; Bis-Trimethylammonium Compounds; Butyrylcholinesterase; | 1963 |
[ON CARDIAC ARREST INDUCED IN MAN DURING ANESTHESIA. POTENTIATION OF THE OCULO-CARDIAC REFLEX WITH ANTICHOLINESTERASE DRUGS].
Topics: Anesthesia; Anesthesia, General; Cholinesterase Inhibitors; Electrocardiography; Eye; Galantamine; H | 1963 |
[STUDIES ON EARLY OPERATIVE DEATHS].
Topics: Anesthesia; Anesthesia, General; Anesthesiology; Hypoxia; Japan; Mortality; Neostigmine; Surgical Pr | 1963 |
[ON THE PROBLEM OF ANESTHESIA IN NEWBORN INFANTS WITH ESOPHAGEAL ATRESIA].
Topics: Anesthesia; Anesthesia, Endotracheal; Esophageal Atresia; Esophageal Stenosis; Humans; Infant; Infan | 1963 |
PUPILLARY AND CIRCULATORY CHANGES AT THE TERMINATION OF RELAXANT ANAESTHESIA.
Topics: Anesthesia; Anesthesia, Endotracheal; Atropine; Blood Pressure; Blood Pressure Determination; Heart | 1963 |
[SENSITIVITY CHANGES OF THE ISOLATED GUINEA PIG INTESTINE BY PREMEDICATION, ANESTHESIA AND SPASMOLYTICS].
Topics: Aminopyrine; Anesthesia; Animals; Atropine; Barium; Bis-Trimethylammonium Compounds; Chlorides; Chlo | 1963 |
[OUR EXPERIENCES WITH GENERAL ANESTHESIA IN HEART SURGERY].
Topics: Anesthesia; Anesthesia, General; Cardiac Surgical Procedures; Humans; Neostigmine; Postoperative Com | 1963 |
MANAGEMENT OF THE PATIENT WITH MYASTHENIA GRAVIS FOR THYMECTOMY.
Topics: Anesthesia; Anesthesia, Inhalation; Anesthesiology; Myasthenia Gravis; Neostigmine; Parasympathomime | 1964 |
TUBOCURARINE ADMINISTRATION BASED UPON ITS DISAPPEARANCE AND ACCUMULATION CURVES IN ANAESTHETIZED MAN.
Topics: Adjuvants, Anesthesia; Anesthesia; Anesthesia, Inhalation; Anesthesiology; Atropine; Body Fluids; Ga | 1964 |
[NEUROMUSCULAR BLOCK CAUSED BY ANTIBIOTICS. RELATIONSHIPS BETWEEN CURARE-LIKE DRUGS AND ANTIBIOTICS. EXPERIMENTS WITH ANTAGONISTS].
Topics: Anesthesia; Anesthesiology; Animals; Anti-Bacterial Agents; Curare; Dihydrostreptomycin Sulfate; Kan | 1964 |
FACTORS AFFECTING THE TERMINATION OF CURARIZATION IN THE HUMAN SUBJECT.
Topics: Acidosis; Alkalosis; Anesthesia; Biomedical Research; Humans; Hydrogen-Ion Concentration; Hyperventi | 1964 |
DIALLYL TOXIFERINE.
Topics: Anesthesia; Anesthesia, Inhalation; Atropine; Bis-Trimethylammonium Compounds; Blood Pressure; Blood | 1964 |
ALTERATIONS IN THE ACTIVITY OF PENTOTHAL, PHENOBARBITAL, PENTYLENETETRAZOL, AND STRYCHNINE BY CHOLINESTERASE INHIBITORS.
Topics: Acetylcholine; Anesthesia; Atropine; Cholinesterase Inhibitors; Isoflurophate; Mice; Neostigmine; Pe | 1964 |
A CLINICAL TRIAL OF HAYATIN METHIODIDE AS A RELAXANT IN 100 CASES.
Topics: Adolescent; Anesthesia; Anesthesia, Endotracheal; Anesthesiology; Blood Pressure; Blood Pressure Det | 1964 |
CHANGES IN PULSE RATE AND BLOOD PRESSURE AFTER EXTUBATION.
Topics: Anesthesia; Anesthesia, Endotracheal; Anesthesiology; Atropine; Biomedical Research; Blood Pressure; | 1964 |
[PREVENTION OF MUSCULAR PAIN AFTER BRONCHOSCOPY UNDER ANESTHESIA WITH DEPOLARIZING MUSCLE RELAXANTS].
Topics: Administration, Intravenous; Anesthesia; Anesthesia, Intravenous; Anesthesiology; Atropine; Bronchos | 1964 |
[GALANTHAMINUM HYDROBROMICUM ("NIVALINE"), A NEW ANTIDOTE OF NON-POLARIZING MUSCLE RELAXANTS. PHARMACOLOGY AND CLINICAL USE].
Topics: Anesthesia; Anesthesiology; Animals; Antidotes; Atropine; Biomedical Research; Bradycardia; Cats; Ga | 1964 |
THE INFLUENCE OF RESERPINE ON HALOTHANE ANAESTHESIA IN MICE.
Topics: Anesthesia; Atropine; Brain Chemistry; Catechols; Epinephrine; Halothane; Hydrazines; Mice; Neostigm | 1964 |
The effect of aropine and neostigmine on the pulse rates of anesthetised patients.
Topics: Anesthesia; Anesthesiology; Atropine; Heart Rate; Humans; Neostigmine; Pulse | 1962 |
Treatment of the hypotensive states of spinal analgesia with dilute neosynephrin solution.
Topics: Analgesia; Anesthesia; Blood Pressure; Humans; Hypotension; Neostigmine | 1951 |
[Post-anesthetic agitation in curare anesthesia].
Topics: Anesthesia; Anesthesiology; Anesthetics; Curare; Humans; Neostigmine; Psychomotor Agitation | 1954 |
Intrathecal neostigmine prevents intrathecal clonidine from attenuating hypercapnic cerebral vasodilation in rabbits.
Topics: Adrenergic alpha-Agonists; Anesthesia; Animals; Arterioles; Cerebrovascular Circulation; Cholinester | 2005 |
Sugammadex: a revolutionary approach to neuromuscular antagonism.
Topics: Androstanols; Anesthesia; Animals; gamma-Cyclodextrins; Humans; Neostigmine; Neuromuscular Blockade; | 2006 |
Muscle relaxants--reversal agents.
Topics: Anesthesia; Antidotes; Curare; History, 20th Century; Humans; Muscle Relaxants, Central; Myasthenia | 2006 |
Irreversible tubocurarine neuromuscular block in the human.
Topics: Adult; Anesthesia; Carbon Dioxide; Humans; Hydrogen-Ion Concentration; Myography; Neostigmine; Neuro | 1967 |
Antagonism of d-tubocurarine-induced neuromuscular blockade with a mixture of 4-aminopyridine and neostigmine in man.
Topics: 4-Aminopyridine; Adult; Aminopyridines; Anesthesia; Blood Pressure; Electromyography; Female; Heart | 1984 |
Intubation conditions and reversibility of a new non-depolarizing neuromuscular blocking agent, Org-NC45.
Topics: Adult; Anesthesia; Blood Pressure; Heart Rate; Humans; Intubation, Intratracheal; Neostigmine; Neuro | 1980 |
The effect of galanthamine hydrobromide on plasma ACTH in patients undergoing anaesthesia and surgery.
Topics: Adrenocorticotropic Hormone; Adult; Anesthesia; Female; Galantamine; Humans; Hydrocortisone; Male; M | 1980 |
A new non-depolarizing myorelaxant with high activity and specificity.
Topics: Anesthesia; Animals; Blood Pressure; Cats; Female; Ganglia, Sympathetic; Male; Mice; Muscle Relaxant | 1982 |
Neostigmine and edrophonium as antagonists of pancuronium in infants and children.
Topics: Anesthesia; Child; Child, Preschool; Edrophonium; Humans; Infant; Infant, Newborn; Muscle Contractio | 1983 |
[Anesthesia in dystrophia myotonica using the capnogram].
Topics: Adolescent; Adult; Anesthesia; Carbon Dioxide; Female; Heart Function Tests; Humans; Male; Middle Ag | 1984 |
Effect of halogenated anaesthetics on heart rate changes during reversal of neuromuscular block with glycopyrrolate and neostigmine.
Topics: Adult; Aged; Anesthesia; Enflurane; Female; Glycopyrrolate; Halothane; Heart Rate; Humans; Male; Mid | 1984 |
Assessment of neuromuscular blockade using tetanic, single-twitch and train-of-four responses: discussion paper.
Topics: Anesthesia; Atracurium; Gallamine Triethiodide; Humans; Isoquinolines; Monitoring, Physiologic; Musc | 1984 |
Monitoring neuromuscular blockade--evaluation of a new rectal electrode/transducer system in cats.
Topics: Alcuronium; Anal Canal; Anesthesia; Animals; Atropine; Cats; Monitoring, Physiologic; Muscle Contrac | 1984 |
Mechanical responses to peroneal nerve stimulation in halothane-anesthetized horses in the absence of neuromuscular blockade and during partial nondepolarizing blockade.
Topics: Anesthesia; Animals; Cats; Edrophonium; Electric Stimulation; Gallamine Triethiodide; Halothane; Hor | 1983 |
Cumulative dose responses to gallamine, pancuronium, and neostigmine in halothane-anesthetized horses: neuromuscular and cardiovascular effects.
Topics: Anesthesia; Animals; Dose-Response Relationship, Drug; Electric Stimulation; Female; Gallamine Triet | 1983 |
Tachyphylaxis after repeated dosage of decamethonium in anaesthetized man.
Topics: Anesthesia; Decamethonium Compounds; Halothane; Humans; Muscle Contraction; Neostigmine; Tachyphylax | 1982 |
Administration of depolarizing muscle relaxants after non-depolarizer reversal -- when is it safe?
Topics: Aged; Anesthesia; Humans; Male; Neostigmine; Postoperative Complications; Time Factors | 1982 |
Neostigmine reversal of D-tubocurarine and pancuronium bromide combinations in man.
Topics: Adult; Anesthesia; Female; Humans; Male; Muscle Contraction; Neostigmine; Pancuronium; Time Factors; | 1982 |
The use of dioxonium as a neuromuscular blocking agent.
Topics: Anesthesia; Dioxolanes; Dioxoles; Electric Stimulation; Humans; Neostigmine; Neuromuscular Blocking | 1980 |
The clinical neuromuscular pharmacology of 51W89 in patients receiving nitrous oxide/opioid/barbiturate anesthesia.
Topics: Adult; Anesthesia; Atracurium; Barbiturates; Dose-Response Relationship, Drug; Humans; Narcotics; Ne | 1995 |
Reversal of residual neuromuscular block with neostigmine at one to four hours after a single intubating dose of vecuronium.
Topics: Adult; Anesthesia; Female; Humans; Male; Middle Aged; Muscle Contraction; Neostigmine; Neuromuscular | 1995 |
Inadequate antagonism of vecuronium-induced neuromuscular block by neostigmine during sevoflurane or isoflurane anesthesia.
Topics: Adult; Anesthesia; Anesthetics; Dose-Response Relationship, Drug; Ethers; Female; Humans; Isoflurane | 1995 |
Neostigmine or beta-blockers? A pharmacologic conundrum.
Topics: Adrenergic beta-Antagonists; Aged; Anesthesia; Aortic Aneurysm; Blood Pressure; Female; Humans; Neos | 1993 |
[Antagonism to neuromuscular effect of subcutaneous administration of pancuronium by neostigmine].
Topics: Adult; Aged; Anesthesia; Humans; Injections, Subcutaneous; Male; Middle Aged; Neostigmine; Neuromusc | 1994 |
Anaesthesia for cardiac transplant patients.
Topics: Anesthesia; Animals; Bradycardia; Cats; Cholinesterase Inhibitors; Heart Rate; Heart Transplantation | 1994 |
Reversal by suramin of neuromuscular block produced by pancuronium in the anaesthetized rat.
Topics: 4-Aminopyridine; Anesthesia; Animals; Electric Stimulation; Isometric Contraction; Male; Neostigmine | 1993 |
Potentiation by choline of basal and electrically evoked acetylcholine release, as studied using a novel device which both stimulates and perfuses rat corpus striatum.
Topics: Acetylcholine; Anesthesia; Animals; Choline; Corpus Striatum; Dialysis; Dopamine; Electric Stimulati | 1993 |
The effects of donepezil and neostigmine in a patient with unusual pseudocholinesterase activity.
Topics: Aged; Aged, 80 and over; Anesthesia; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Dr | 1998 |
Interaction of halothane with non-depolarizing neuromuscular blocking drugs in man.
Topics: Anesthesia; Atropine; Drug Interactions; Gallamine Triethiodide; Halothane; Humans; Muscle Contracti | 1979 |
The effect of physostigmine and neostigmine on ketamine anaesthesia and analgesia [proceedings].
Topics: Analgesics; Anesthesia; Animals; Drug Interactions; Ketamine; Male; Neostigmine; Physostigmine; Rats | 1979 |
[Malignant hyperpyrexia following the reversal of muscle relaxant: a case report of non-rigidity type (author's transl)].
Topics: Adult; Anesthesia; Atropine; Humans; Male; Malignant Hyperthermia; Neostigmine | 1978 |
Anesthetic management for direct approach to carotid-cavernous fistula: case report.
Topics: Adult; Anesthesia; Arteriovenous Fistula; Atropine; Carotid Artery Diseases; Cavernous Sinus; Dexame | 1977 |
Relaxant reversal.
Topics: Anesthesia; Atropine; Child; Humans; Neostigmine; Parasympatholytics | 1977 |
Anesthesia and the porphyrias.
Topics: 5-Aminolevulinate Synthetase; Acute Disease; Aminolevulinic Acid; Ammonia-Lyases; Anesthesia; Anesth | 1975 |
Serum creatine kinase activity as a selection criterion for stress susceptibility after standardised stress in pigs.
Topics: Adrenocorticotropic Hormone; Anesthesia; Animals; Creatine Kinase; Female; Halothane; Isoenzymes; Ma | 1991 |
A dose-response evaluation of pipecuronium bromide in elderly patients under balanced anesthesia.
Topics: Aged; Androstane-3,17-diol; Androstanols; Anesthesia; Dose-Response Relationship, Drug; Female; Huma | 1989 |
Neostigmine and edrophonium antagonism of varying intensity neuromuscular blockade induced by atracurium, pancuronium, or vecuronium.
Topics: Anesthesia; Atracurium; Edrophonium; Enflurane; Halothane; Humans; Isoquinolines; Kinetics; Neostigm | 1986 |
In pursuit of relaxation.
Topics: Anesthesia; Atracurium; Curare; Decamethonium Compounds; History, 20th Century; Humans; Muscle Contr | 1986 |
Neostigmine antagonism of vecuronium paralysis during fentanyl, halothane, isoflurane, and enflurane anesthesia.
Topics: Adult; Anesthesia; Enflurane; Fentanyl; Halothane; Humans; Middle Aged; Neostigmine; Neuromuscular J | 1987 |
[Antagonism of an intubation dose of vecuronium].
Topics: Anesthesia; Edrophonium; Halothane; Humans; Intubation; Muscle Contraction; Muscle Relaxation; Neost | 1987 |
Tracheal rupture--an anaesthetic mishap?
Topics: Anesthesia; Atropine; Humans; Neostigmine | 1986 |
Multiple neuromuscular blocking agents and reversal in a patient with absent plasma cholinesterase.
Topics: Adult; Anesthesia; Cholinesterases; Female; Genotype; Humans; Neostigmine; Neuromuscular Blocking Ag | 1986 |
Respiratory problems after atropine and neostigmine in dogs.
Topics: Anesthesia; Animals; Atracurium; Atropine; Dog Diseases; Dogs; Isoquinolines; Neostigmine; Neuromusc | 1985 |
Verapamil potentiation of neuromuscular blockade: failure of reversal with neostigmine but prompt reversal with edrophonium.
Topics: Anesthesia; Cardiomyopathy, Hypertrophic; Cholecystectomy; Drug Synergism; Edrophonium; Humans; Male | 1985 |
[Electromyographic studies of the supposed interference of Trasylol in neuromuscular block induced with curariform drugs].
Topics: Anesthesia; Animals; Aprotinin; Decamethonium Compounds; Dogs; Drug Antagonism; Edrophonium; Electro | 1968 |
Clinical study of pancuronium bromide as a neuromuscular blocking agent in anaesthesia.
Topics: Adult; Androstanes; Anesthesia; Atropine; Blood Pressure; Body Weight; Female; Heart Rate; Humans; I | 1971 |
Paediatric pharmacology.
Topics: Age Factors; Aminobenzoates; Anesthesia; Animals; Atropine; Autonomic Nervous System; Bis-Trimethyla | 1973 |
Tetrahydroaminacrine in anaesthesia.
Topics: Anesthesia; Animals; Atropine; Central Nervous System Stimulants; Drug Incompatibility; Drug Synergi | 1965 |
Interruption of a drug regimen before anesthesia.
Topics: Anesthesia; Anti-Infective Agents; Anticoagulants; Anticonvulsants; Antidepressive Agents; Antihyper | 1974 |
Anaesthesia for renal transplantation. A preliminary report.
Topics: Anesthesia; Anesthesia, Spinal; Blood Pressure Determination; Cadaver; Cyclopropanes; Ethers; Ethyl | 1970 |
Glycopyrrolate as a substitute for atropine in neostigmine reversal of muscle relaxant drugs.
Topics: Anesthesia; Atropine; Bradycardia; Curare; Drug Combinations; Female; Glycopyrrolate; Heart Rate; Hu | 1972 |
Dystrophia myotonica: a multisystem disease.
Topics: Anesthesia; Atropine; Cholinesterases; Electromyography; Halothane; Humans; Male; Melanoma; Middle A | 1972 |
Anaesthesia in pigs. Intramuscular ketamine as an induction agent.
Topics: Anesthesia; Anesthetics; Animals; Atropine; Cyclohexanes; Gallamine Triethiodide; Injections, Intram | 1971 |
Tachyphylaxis and toxicity of 5HT in anaesthetized rats.
Topics: 5-Hydroxytryptophan; Anesthesia; Animals; Creatinine; Imipramine; Injections, Intravenous; Injection | 1969 |
Data on the anticholinesterase effect of narcotin.
Topics: Anesthesia; Animals; Blood Pressure; Cats; Drug Synergism; Neostigmine; Noscapine; Pilocarpine | 1967 |
[Anesthesia with combined nitrous oxide, oxygen and tubocurarine chloride for children (Jackson Rees's method). 1].
Topics: Anesthesia; Carbon Dioxide; Child; Child, Preschool; Female; Humans; Hydrogen-Ion Concentration; Inf | 1968 |
The belladonna drugs.
Topics: Anesthesia; Atropa belladonna; Atropine; Blood Pressure; Bradycardia; Cardiac Output; Central Nervou | 1968 |
[Cardiocirculatory effects of diazepam and their relations to the cholinergic system].
Topics: Acetylcholine; Anesthesia; Animals; Blood Circulation; Blood Pressure; Diazepam; Dogs; Heart; Heart | 1968 |
[Iatrogenic interference with neuromuscular block induced with thiamine].
Topics: Anesthesia; Animals; Anti-Arrhythmia Agents; Autonomic Nerve Block; Dogs; Neostigmine; Plants, Medic | 1968 |
[On the problem of muscle relaxants].
Topics: Anesthesia; Gallamine Triethiodide; Humans; Muscles; Neostigmine; Succinylcholine; Tubocurarine | 1966 |